Insider buying last 90 days
No open-market insider purchases were filed for BNTX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every BNTX insider filing, plotted on the chart in Gekko.Open BNTX in Gekko
Gekko Brief
AI summaryThis week's news centers on BioNTech's decision to close three sites in Germany and one in Singapore after failing to find buyers, part of its pivot away from pandemic-era manufacturing. Alongside this, CEO Ugur Sahin reported further share sales under a Rule 10b5-1 trading plan established in June 2026, including 27,000 and 34,000 ordinary shares priced at $98.6882 and $98.4682. Separately, coverage compared BioNTech's oncology pipeline and financial flexibility to Moderna's recent cancer trial results.
BNTX closed at $99.08, up 0.6%, sitting above both its 50-day average of $98.08 and 200-day average of $97.65, with the shorter average above the longer one. The GekkoIndex reads 59.6, placing the stock in the Neutral zone, down 0.8 over five days. Price stands 15% above Gekko Fair Value of $86.16, a gap that has drawn a headwind designation in trend analysis.
The next earnings report is set for 3 November 2026, before the open, which falls outside a typical 20-trading-day holding window; the prior quarter saw an EPS miss against estimates with a muted 0.1% reaction. No insider, Congress, or unusual options activity appears in the current window. Seasonality over the next 20 trading days has averaged -2.5% across 5 years, rising in 3 of those years. Analyst consensus among 14 firms shows 11 buy and 3 hold ratings, with a consensus target of $117.24.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
BioNTech price vs fair value
Close $99.08200-day averageGekko Fair Value $86.16
BioNTech quick facts
- Market cap
- $24.89B
- P/E ratio
- —
- Forward P/E
- 7
- EPS, TTM
- −$7.75
- Revenue, TTM
- $2.65B
- Profit margin
- -63.6%
- Dividend yield
- —
- Beta
- 1.29
- Volume
- 777,885 avg 853,682
- 1-year return
- +1.0%
- Typical daily move
- ±3.2%
- Typical 20-day move
- ±7.5%
- 50-day average
- $98.08
- 200-day average
- $97.65
- Next earnings
- Nov 3 before open
- Shares outstanding
- 251.2M
BioNTech swing-trade checklist
BioNTech scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $99.08 is above the 50-day ($98.08) and 200-day ($97.65) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
59.6, Neutral
Reading 59.6 is in the Neutral zone.
See the GekkoIndex - Fair valueheadwind
15.0% above
Price is 15% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 35 days
Next report Nov 3, 2026, 35 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
−2.5% on average
From this point in the calendar, the next 20 trading days averaged −2.5% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
BioNTech stock chart and price history
BioNTech closed at $99.08 on Sep 28, 2026, +1.0% over the past year, inside a 52-week range of $79.52 to $124.00.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −11.1%
- 3 months
- +5.1%
- 6 months
- +15.6%
- 1 year
- +1.0%
The full BNTX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open BNTX in Gekko
Follow BioNTech through every session
Put BNTX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track BNTX in GekkoFree for 7 days. No credit card required.
About BioNTech
BioNTech develops immune-based treatments aimed at cancer and infectious disease. It is widely recognized for its work on cancer vaccines and personalized immunotherapies designed to help the body's own immune system target tumors, alongside preventative vaccines addressing illnesses such as COVID-19 and influenza. Its research also extends to protein replacement approaches for rare conditions.
The company's pipeline spans several distinct treatment classes, including cancer vaccine candidates, neoantigen-targeted therapies, mRNA-based immunotherapies delivered directly into tumors, engineered immune cell treatments, checkpoint modulators, antibody-based candidates and small molecule compounds, most still moving through early to mid-stage clinical trials. To carry this work forward, BioNTech works alongside other pharmaceutical and biotechnology organizations, among them Genentech, Sanofi, Genmab, Pfizer, Shanghai Fosun Pharmaceutical and Regeneron.
BioNTech was founded in 2008 and is headquartered in Mainz, Germany. Its shares trade under the ticker BNTX.
- Sector
- Health technology
- Website
- biontech.de
BioNTech GekkoIndex: the smart money zone
BioNTech’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 59.6, in the Neutral zone, down 0.8 points over five sessions.
59.6Neutral
Down 0.8 points over five sessions, from the Accumulation zone.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 20 | +3.6% | +6.0% | ||
| Accumulation | 212 | +0.5% | +4.6% | ||
| Neutral (current zone) | 364 | 0.0% | −0.9% | ||
| Distribution | 25 | +0.1% | −4.9% | ||
| Selling | 4 | Too few readings yet | |||
Average BNTX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the BNTX price, zone by zone.Track BNTX in Gekko
Is BioNTech stock overvalued? Gekko Fair Value
BioNTech trades 15.0% above Gekko Fair Value of $86.16, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what BioNTech shares are worth, recalculated every trading day.
$86.16
Gekko Fair Value, Sep 26, 2026
15.0% Overvalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open BNTX in Gekko
BioNTech insider and Congress trading
No open-market insider purchases were filed for BioNTech, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in BNTX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for BNTX, plotted on the chart in Gekko.Open BNTX in Gekko
Hedge funds and billionaires quarter ended Jun 30
0of the funds Gekko tracks hold BNTX.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
BioNTech earnings: next date and track record
BioNTech reports on Nov 3, 2026, before the open (35 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Nov 3, 2026
Expected before the open, 35 days away
- EPS estimate
- $0.84
- Revenue estimate
- $1.20B
4 of 8reports beat the EPS estimate
±3%average move across the report
2 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 4, 2026 AI summary
- What they said
- BioNTech's Q2 2026 call highlighted leadership transition with Guido Oelkers appointed as incoming CEO effective February 1. The company is accelerating late-stage oncology development, including promising Phase II/III data for pumitamig in first-line NSCLC presented at ASCO. BioNTech dosed the first patient in a Phase III trial for B7-H3 ADC elfetabart Drozuntecan in metastatic castration-resistant prostate cancer. The company is expanding novel combination ADC programs targeting a multiproduct portfolio by 2030.
- Guidance
- BioNTech targets more than 17 late-stage and pivotal trial readouts through 2030 across multiple tumor types. Management expects strong second-half 2026 execution momentum, positioning the company to become a diversified multiproduct biopharmaceutical company by 2030.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 4, 2026 | −$3.03 est −$2.58 | $120.6M est $180.2M | −0.1% |
| May 5, 2026 | −$1.95 est −$1.92 | $136.4M est $207.4M | −4.1% |
| Nov 3, 2025 | −$0.14 est −$1.12 | $1.78B est $843.7M | +0.9% |
| Aug 4, 2025 | −$1.82 est −$2.69 | $307.1M est $177.8M | +3.5% |
| May 5, 2025 | −$1.73 est −$2.35 | $200.4M est $215.1M | −9.7% |
| Nov 4, 2024 | $0.88 est −$1.70 | $1.39B est $572.4M | −0.5% |
| Aug 5, 2024 | −$3.36 est −$2.02 | $138.4M est $145.4M | −3.1% |
| May 6, 2024 | −$1.41 est −$1.17 | $201.5M est $479.5M | −2.0% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
BioNTech stock forecast and analyst price targets
Analysts’ average 12-month price target for BioNTech is $117.24, +18.3% from the last close, from 14 firms rating the stock in the last 90 days.
$117.24consensus 12-month target, +18.3% from the last close
Now $99.08Avg $117.24
Low $96High $140
Each firm’s latest rating in the last 90 days: 14 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 28 | Morgan Stanley | $115 | +16.1% |
| Sep 25 | Bernstein | $96 | −3.1% |
| Sep 24 | Wells Fargo | $140 | +41.3% |
| Sep 23 | Canaccord Genuity | $136 | +37.3% |
| Sep 21 | Morgan Stanley | $115 | +16.1% |
−0.9%average 20-day move after past Neutral readings
−2.5%average move over the next 20 trading days in the last 5 years
±3.2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
BioNTech seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, BioNTech averaged −2.5% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.3% | 4 of 5 |
| Next 10 trading days | −0.7% | 3 of 5 |
| Next 15 trading days | −5.2% | 1 of 5 |
| Next 20 trading days | −2.5% | 3 of 5 |
| Next 30 trading days | −1.1% | 2 of 5 |
For scale, BNTX’s typical 20-trading-day move in either direction is about 7.5%.
BioNTech market cap and key statistics
BioNTech’s market cap is $24.89B and revenue of $2.65B over the last twelve months.
Valuation
- Market cap
- $24.89B
- Forward P/E
- 7
- EPS, TTM
- −$7.75
- Gekko Fair Value
- $86.16
Trading
- Volume
- 777,885
- Avg volume, 20 days
- 853,682
- 52-week high
- $124.00
- 52-week low
- $79.52
- Shares outstanding
- 251.2M
Financials
- Revenue, TTM
- $2.65B
- Profit margin
- -63.6%
- Return on equity
- -9.3%
- Quarterly earnings growth, YoY
- −43.2%
Risk and income
- Beta
- 1.29
- Typical daily move
- ±3.2%
- Typical 20-day move
- ±7.5%
BioNTech stock news this week
Coverage of BioNTech this week reads positive: 6 positive, 3 neutral and 5 negative headlines.
- A trading plan covers BioNTech (BNTX) CEO Ugur Sahin's sales of 27,000 and 34,000 shares.Stock Titan, Sep 28
- BioNTech to Close 3 German Sites After Unsuccessful Sale Effortsmarketscreener.com, Sep 28
- Moderna vs. BioNTech: Which mRNA Cancer Stock Has More Upside?The Globe and Mail, Sep 28
- BioNTech to close 3 German plantsBreakingthenews.net, Sep 28
- BioNTech to shutter sites in Germany, Singapore as no buyers emergeReuters, Sep 28
- How New Lung Cancer Data And Updated COVID Shot At BioNTech (BNTX) Has Changed Its Investment StoryYahoo Finance Singapore, Sep 27
BioNTech stock FAQ
What is BioNTech’s market cap?
BioNTech’s market cap is $24.89B at the Sep 28, 2026 close of $99.08, with 251.2M shares outstanding.
What is the BioNTech stock forecast?
The consensus analyst 12-month price target for BioNTech is $117.24, +18.3% from the last close. Of the 14 firms that rated the stock in the last 90 days, 11 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is BioNTech stock overvalued or undervalued?
On Gekko’s estimate BioNTech is overvalued: the Sep 28, 2026 close of $99.08 is 15.0% above Gekko Fair Value of $86.16. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does BioNTech report earnings next?
BioNTech is expected to report on Nov 3, 2026, before the market opens (35 days away). Analysts expect earnings of $0.84 per share on revenue of $1.20B. BioNTech beat the earnings estimate in 4 of its last 8 reports, moving 3% on average across the report.
What is BioNTech’s 52-week high and low?
BioNTech’s 52-week high is $124.00 and its 52-week low is $79.52; it closed at $99.08 on Sep 28, 2026, +1.0% over the past year. Over the last five years the shares peaked at $374.58 on Nov 29, 2021.
Is BioNTech stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 2 as mixed (gekkoindex and seasonality) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See BioNTech the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.